Empirical Asset Management LLC Takes $12.15 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Empirical Asset Management LLC purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 51,614 shares of the biopharmaceutical company's stock, valued at approximately $12,145,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Huntington National Bank boosted its holdings in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 45 shares during the period. Hollencrest Capital Management purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $29,000. Washington Trust Advisors Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $42,000. True Wealth Design LLC boosted its position in shares of Alnylam Pharmaceuticals by 15,300.0% during the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 153 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $45,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Trading Down 1.2 %

ALNY stock traded down $2.89 on Friday, reaching $246.27. The company's stock had a trading volume of 556,461 shares, compared to its average volume of 679,404. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The business has a fifty day simple moving average of $246.62 and a two-hundred day simple moving average of $259.70. The firm has a market cap of $31.76 billion, a PE ratio of -94.00 and a beta of 0.34. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analysts' expectations of $532.91 million. During the same quarter last year, the firm earned $1.15 earnings per share. The company's quarterly revenue was down 33.3% on a year-over-year basis. As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ALNY. Barclays raised their target price on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an "overweight" rating in a research note on Friday, November 1st. Chardan Capital reaffirmed a "buy" rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. TD Cowen increased their target price on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Canaccord Genuity Group raised their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a "buy" rating in a research report on Friday, November 1st. Finally, Raymond James upped their price objective on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an "outperform" rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $298.61.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the transaction, the chief marketing officer now directly owns 17,457 shares of the company's stock, valued at $4,381,357.86. This trade represents a 8.79 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Yvonne Greenstreet sold 5,219 shares of the company's stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the completion of the sale, the chief executive officer now owns 78,880 shares in the company, valued at approximately $19,797,302.40. This trade represents a 6.21 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,122 shares of company stock valued at $2,540,455. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.